Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1956-1963

  Tichomirowa, Maria A ^a   Theodoropoulou, Marily ^a   Daly, Adrian F ^b   Yassouridis, Alexander ^a   Hansen, Sabine ^c   Lu, Jie ^a   Lange, Manfred ^d   Goldbrunner, Roland H ^a   Stalla, Günter K ^a   Renner, Ulrich ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF MUNICH   (Germany)

^d Department of Pediatrics   (Germany)

Author keywords

Fluvastatin; MAP kinase inhibitors; Meningiomas; Paclitaxel; TLR4

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; TOLL LIKE RECEPTOR 4;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PACLITAXEL; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TOLL-LIKE RECEPTOR 4; TUMOR CELLS, CULTURED;

EID: 51949089448     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23737     Document Type: Article

References (34)

1. Central Brain Tumor Registry of the United States 2005-2006 statistical report, CBTRUS, 2007.
2. Heinrich B, Hartmann C, Stemmer-Rachamimov AO, Louis DN, MacCollin M. Multiple meningiomas: investigating the molecular basis of sporadic and familial forms. Int J Cancer 2003;103:483-8.
3. Ragel B, Jensen RL. New approaches for the treatment of refractory meningiomas. Cancer Control 2003;10:148-58.
4. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005;57:538-50.
5. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 2004;229:567-85.
6. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 2002;56:133-42.
7. Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 2001;94:293-300.
8. Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int J Immunopharmacol 2003;3:1699-714.
9. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol J Endotoxin Res 2001;7:232-6.
10. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2003;2:641-9.
11. Pushkarev VM, Starenki DV, Saenko VA, Namba H, Kurebayashi J, Tronko MD, Yamashita S. Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology 2004;145:3143-52.
12. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001;1:141-9.
13. Corsini A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int J Clin Pract 2004;58:494-503.
14. Braun B, Lange M, Oeckler R, Mueller MM. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 2004;68:131-40.
15. Pagotto U, Arzberger T, Hopfner U, Sauer J, Renner U, Newton CJ, Lange M, Uhl E, Weindl A, Stalla GK. Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J Clin Invest 1995;96:2017-25.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
17. Tichomirowa M, Theodoropoulou M, Lohrer P, Schaaf L, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U. Bacterial endotoxin (lipopolysaccharide) stimulates interleukin-6 production and inhibits growth of pituitary tumour cells expressing the toll-like receptor 4. J Neuroendocrinol 2005;17:152-60.
18. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26:199-213.
19. Newton CJ, Ran G, Xie YX, Bilko D, Burgoyne CH, Adams I, Abidia A, McCollum PT, Atkin SL. Notice of inadvertent duplicate publication: statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2005;187:167.
20. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. 'Malignancy' in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85:2046-56.
21. Lusis E, Gutmann DH. Meningioma: an update. Curr Opin Neurol 2004;17:687-92.
22. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7.
23. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-5014.
24. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005;295:179-85.
25. Kelly MG, Alvero AB, Chen R, Silasi DA. Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006;66:3859-68.
26. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005;65:11771-8.
27. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, Kleeberger SR. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 2005;97:1778-81.
28. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98.
29. Humphries HE, Triantafilou M, Makepeace BL, Heckels JE, Triantafilou K, Christodoulides M. Activation of human meningeal cells is modulated by lipopolysaccharide (LPS) and non-LPS components of Neisseria meningitidis and is independent of Toll-like receptor (TLR)4 and TLR2 signalling. Cell Microbiol 2005;7:415-30.
30. Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nature Immunol 2004;5:495-502.
31. Tonn JC, Ott MM, Bouterfa H, Kerkau S, Kapp M, Müller-Hermelink HK, Roosen K. Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas. Neurosurgery 1997;41:1152-9.
32. Tonn JC, Ott MM, Meixensberger J, Paulus W, Roosen K. Progesterone receptors are detectable in tumor fragment spheroids of meningiomas in vitro. Anticancer Res 1994;14:2453-2456.
33. Wang TH, Chan YH, Chen CW, Kung WH, Lee YS, Wang ST, Chang TC, Wang HS. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 2006;25:4857-66.
34. Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001;268:84-92.